Search research articles
Contact Us
Filters
Showing results (21-30 of 44) with videos related to
Page
of 5
Sort By:
Neurobiology of Aging
|
May 29, 2007
Complete ascertainment of Parkinson disease in the Swedish Twin Registry
Karin Wirdefeldt, Margaret Gatz, Stephanie L Bakaysa, et al.
Neuroepidemiology
|
April 5, 2012
Accuracy and sensitivity of Parkinsonian disorder diagnoses in two Swedish national health registers
Adina L Feldman, Anna L V Johansson, Margaret Gatz, et al.
Expert Review of Neurotherapeutics
|
November 5, 2016
Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspective
Stuart H Isaacson, Stanley Fisher, Fiona Gupta, et al.
Clinical Parkinsonism & Related Disorders
|
December 10, 2021
AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutions
Mark F Lew, Robert A Hauser, Stuart H Isaacson, et al.
Biomarkers in Medicine
|
July 3, 2019
Oligomeric α-synuclein is increased in basal tears of Parkinson's patients
Sarah F Hamm-Alvarez, Curtis T Okamoto, Srikanth R Janga, et al.
Parkinsonism & Related Disorders
|
May 13, 2015
Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials
Mark F Lew, John T Slevin, Rejko Krüger, et al.
Neurocase
|
February 4, 2026
A novel mutation in colony-stimulating factor 1 receptor (CSF1R) causing CSF1R-related disorder (CSF1R-RD)
Anup N Sonti, Elizabeth Joe, Jillian V Berry, et al.
Journal of the Neurological Sciences
|
April 23, 2017
Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry
Richard M Trosch, Alberto J Espay, Daniel Truong, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
March 1, 2005
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study
Daniel Truong, Drake D Duane, Joseph Jankovic, et al.
Clinical Neuropharmacology
|
October 27, 2009
Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects
Kelly E Lyons, Joseph H Friedman, Neal Hermanowicz, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 44) with videos related to
Sort By:
Page
of 5
Neurobiology of Aging
|
May 29, 2007
Complete ascertainment of Parkinson disease in the Swedish Twin Registry
Karin Wirdefeldt, Margaret Gatz, Stephanie L Bakaysa, et al.
Neuroepidemiology
|
April 5, 2012
Accuracy and sensitivity of Parkinsonian disorder diagnoses in two Swedish national health registers
Adina L Feldman, Anna L V Johansson, Margaret Gatz, et al.
Expert Review of Neurotherapeutics
|
November 5, 2016
Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspective
Stuart H Isaacson, Stanley Fisher, Fiona Gupta, et al.
Clinical Parkinsonism & Related Disorders
|
December 10, 2021
AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutions
Mark F Lew, Robert A Hauser, Stuart H Isaacson, et al.
Biomarkers in Medicine
|
July 3, 2019
Oligomeric α-synuclein is increased in basal tears of Parkinson's patients
Sarah F Hamm-Alvarez, Curtis T Okamoto, Srikanth R Janga, et al.
Parkinsonism & Related Disorders
|
May 13, 2015
Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials
Mark F Lew, John T Slevin, Rejko Krüger, et al.
Neurocase
|
February 4, 2026
A novel mutation in colony-stimulating factor 1 receptor (CSF1R) causing CSF1R-related disorder (CSF1R-RD)
Anup N Sonti, Elizabeth Joe, Jillian V Berry, et al.
Journal of the Neurological Sciences
|
April 23, 2017
Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry
Richard M Trosch, Alberto J Espay, Daniel Truong, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
March 1, 2005
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study
Daniel Truong, Drake D Duane, Joseph Jankovic, et al.
Clinical Neuropharmacology
|
October 27, 2009
Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects
Kelly E Lyons, Joseph H Friedman, Neal Hermanowicz, et al.
Page
of 5